Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786873 · ClinicalTrials.gov registry record · Phase 3
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
A Phase 3 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT04786873 is a Phase 3 study that has completed, run by AEterna Zentaris. The registered enrollment target is 101 participants.
The verdict
NCT04786873, a Phase 3 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This research study will find out if a new growth hormone stimulation test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children. The stimulation test will use a new growth hormone stimulating substance called macimorelin. By now, only adults in the USA can get this new stimulation test. The results of this study are expected to help children and teenagers with suspected GHD to get the macimorelin stimulation test. The macimorelin test will be compared to a clonidine and an arginine test. Both are known standard stimulation tests. Altogether two macimorelin tests are planned to be performed in the study, to show how repeatable macimorelin tests results are (under a set of similar conditions).
Interventions
- DRUG Macimorelin
- DIAGNOSTIC_TEST Arginine
- DIAGNOSTIC_TEST Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2024-06-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04786873
The ClinicalTrials.gov registry entry for NCT04786873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Macimorelin is the first listed.
NCT04786873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04786873 about?
NCT04786873 is a clinical study titled "A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is". This research study will find out if a new growth hormone stimulation test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children. The stimulation test will use a new growth hormone stimulating substance called macimorelin. By now, only adults in the USA can...
What is the current status of trial NCT04786873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2021-11-16. Estimated completion is 2024-06-13.
What interventions are being tested in trial NCT04786873?
The interventions under investigation include: Macimorelin (DRUG), Arginine (DIAGNOSTIC_TEST), Clonidine (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04786873?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.